Rachel Havard is a Partner and Chartered Trade Mark Attorney. Rachel handles a wide range of UK and international trade mark cases. Her portfolio of clients covers a variety of sectors, including fashion retail, automotives, medical devices and pharmaceuticals.
The Legal 500 2019 edition has now been published and we are delighted that the firm has once again been ranked as a leading firm for both patents and trade marks, and that our level of service was recognised, once again, as “outstanding”: “The ‘excellent’ A.A. Thornton & Co. ‘goes the extra mile to provide outstanding customer service’ and has… Read more »
Brexit: EU Trade Marks and Community Designs, including if there is ‘no deal’ What is the current situation? The UK is to leave the EU (“Brexit”) on 29 March 2019. When Brexit becomes fully effective, EU unitary trade mark registrations (“EUTMs”) and registered Community designs (“RCDs”) will cease to have effect in the UK,… Read more »
The UK is to leave the EU (“Brexit”) in March 2019, but a transitional (“implementation”) period is expected to apply until at least 31 December 2020, in which existing IP rights obtained under EU law and therefore affected by Brexit will continue to have effect in the UK. When Brexit becomes fully effective, EU unitary… Read more »
Trade Mark Partner Rachel Havard and Consulting Patent Attorney Julie Barrett Major will represent the firm at the Spring Pharmaceutical Trade Marks Group conference in Porto, Portugal from 18th – 20th March. PTMG is a not for profit organisation and their primary objective is to enable members to meet at regular intervals to consider problems… Read more »
EU Trade Marks and Community Designs – Deal, no deal, or no Brexit at all? What is the current situation? Considerable doubt remains about how, when or even if the UK will leave the EU. However, if the UK leaves without a deal then the outcome in relation to IP should be essentially the… Read more »
“If your hair is done properly and you’re wearing good shoes, you can get away with anything.” – Iris Apfel Introduction Not according to the EUIPO in the recent decision in Opposition No. B002757717 of J. Choo Limited v Liangliang Ren, when the Opposition Division handed down a decision to reject the mark: … Read more »
EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit This article was updated: 8 October 2018 Introduction to the Falsified Medicines Directive Directive 2011/62/EU, better known as “The Falsified Medicines Directive” or “FMD”, came into force on 2 January 2013, with the aim of preventing falsified medicines from entering the legitimate supply… Read more »